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Abstract
A suspected oncoprotein, human development regulated GTP-binding protein (DRG) has never been identified though
homologues were found in mouse, Xenopus, Drosophila, yeast and Halobacteria. During a search for SCL binding partners
using the yeast 2-hybrid system, we isolated two independent cDNA clones (clone L51 and clone V3) of the human DRG
homologue from human fetal liver and human thymus cDNA libraries. Only one amino acid difference was found between
human and mouse DRG proteins. Although a human DRG has been previously deposited in the SWISS-PROT Database,
we believe that we have cloned the bona fide human DRG based on the highly conserved primary amino acid structure
between our cloned human homologue and the mouse DRG. ß 1998 Elsevier Science B.V. All rights reserved.
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Development regulated GTP-binding protein
(DRG) is an evolutionarily conserved GTP-binding
protein which has homologues in mouse, Xenopus,
Drosophila, yeast and Halobacteria [1,2]. Mouse
DRG is comprised of 367 amino acids (aa) with a
predicted molecular mass of 40.5 kDa, and contains
¢ve structural motifs characteristic of the GTP-bind-
ing protein [1]. Although relatively higher levels of
DRG gene expression are detected in embryonic tis-
sues, DRG mRNA and protein are down-regulated
during development, and can be demonstrated in a
wide spectrum of adult mouse tissues and cell lines
[3]. The fact that higher DRG mRNA levels were
detected in both embryonic and postnatal mouse thy-
mus has led to speculation that DRG gene expression
may be implicated in T-cell di¡erentiation and matu-
ration [3].
Recently, the mouse DRG has been reported to
bind an amino-terminal-truncated human SCL pro-
tein [4]. SCL (tal-1 or TCL5) is a highly conserved
basic domain helix^loop^helix (bHLH) protein that
is required for normal hematopoietic development
[5^7]. Moreover, the SCL gene is frequently dis-
rupted and dysregulated in T-cell acute lymphoblas-
tic leukemia [8]. Several studies have recently shown
that SCL expression targeted to the thymus leads to
T-cell leukemia in transgenic mice [9^11].
We used the full-length SCL protein [12] as a bait
in a yeast 2-hybrid screen to avoid bias against in-
teraction which involved the amino-terminal portion
of the SCL protein. The Saccharomyces cerevisiae
YRG-2 strain is de¢cient in its ability to synthesize
histidine; this strain has been engineered to express
the HIS3 and lacZ gene products from a GAL4
binding site. Therefore, any interaction with SCL
can be identi¢ed by colony growth on media lacking
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histidine and con¢rmed by an assay for the produc-
tion of L-galactosidase [13]. Twenty-four cDNA
clones were isolated from human fetal brain (Strata-
gene), human fetal liver and human thymus cDNA
libraries (Clontech) [14]. Most of the clones encoded
the E-proteins ITF-1, ITF-2, or HEB, which are
bHLH proteins known to interact with SCL. How-
ever, one cDNA clone (clone L51) from the human
fetal liver cDNA library was found to be homolo-
gous to mouse DRG [1]. An additional clone of hu-
man DRG (clone V3) was also isolated from the hu-
man thymus cDNA library. To verify the speci¢city
of the interaction between human SCL and DRG,
GAL4 transactivation activity was reconstituted
with the GAL4 DNA-binding domain^SCL fusion
protein (pGBT9SCL) and the GAL4 activation do-
main^DRG fusion protein in YRG-2 yeast cells
(Stratagene) (Fig. 1). The speci¢c interaction between
human SCL and DRG was displayed by the expres-
sion of the HIS3 and lacZ genes driven by a func-
tionally reconstituted GAL4 in yeast cells (Fig. 1).
Sequence analysis of clone V3 revealed a DNA
insert of 1647 bp which contains an open reading
frame encoding 367 aa (Fig. 2). A consensus Kozak
sequence is present at the ¢rst ATG codon, and two
potential polyadenylation signal sequences are within
the 3P UTR. Although 90% homology was found
Fig. 1. Speci¢c interaction of human DRG and SCL in the
yeast cells. (A) Schematic description of the experiment and
plating pattern. The pairs in each segment indicate the GAL4
DNA-binding domain fusion protein and GAL4 activation do-
main fusion protein. GBD represents the vector which encodes
only the GAL4 DNA-binding domain, while GAD indicates
the vector which encodes only the GAL4 activation domain.
SIL [21] and p53 are proteins dissimilar to SCL used as nega-
tive controls; the interaction between SCL and ITF-2 is shown
as a positive control. Since the GAL4 DNA-binding domain
vectors contain a TPR cassette, which allows growth on SD
media lacking tryptophan, and the GAL4 activation domain
vectors contain a LEU cassette, which allows growth on SD
media lacking leucine, growth on media lacking tryptophan and
leucine veri¢es that the transformation was successful. (B) Half
of the cotransformation of fusion protein pairs (shown in A)
were plated on SD (^Leu/Trp) medium plates to show the suc-
cessful transformation. (C) Another half of the cotransforma-
tion of fusion protein pairs in YRG-2 yeast cells were plated
on SD (^Leu/Trp/His) medium plates to show the speci¢c inter-
action between SCL and DRG; growth on the SCL/ITF-2 sex-
tant serves as a positive control.
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Fig. 2. The cDNA sequence and primary structure of human
DRG. The complete sequence was derived from clone V3. The
sequence of clone L51 encompasses nt 110 to nt 1375. The stop
codon is indicated by an asterisk. The polyadenylation signal
sequences are underlined. The position of the nucleotides was
indicated on the right, while the amino acids are numbered on
the left.
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Fig. 3. Comparison of human and mouse DRG, with SWISS-PROT P55039 (previously deposited as human DRG) protein sequences.
Amino acid identity is indicated with a vertical line, whereas the di¡erent amino acid identity between human and mouse DRG is
marked with an asterisk. The amino acid identity between the human DRG identi¢ed in this report and mouse DRG is 99.7%, where-
as only 58.2% amino acid identity is found between mouse DRG and the P55039 protein.
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between the human and mouse DRG cDNA coding
sequences, no similarity exists in the 5P and 3P un-
translated regions. Clone L51 begins at nt 110 and
ends at nt 1375 (Fig. 2); the N-terminal 16 aa are
lost in the conceptual coding region. A polyadenyla-
tion signal sequence is present 23 bp upstream of a
polyA tail of clone L51, while clone V3 continued
further downstream, suggesting that there may be
alternative polyadenylation sites within the DRG
mRNA (Fig. 2), indeed, three species (2.8 kb, 1.8 kb
and 1.3 kb) of DRG mRNA have been demonstrated
in Xenopus laevis embryos with variable expression
levels during development [2].
A BLAST search indicated that a locus designated
‘DRG_HUMAN’ had already been deposited in the
SWISS-PROT Database (accession P55039). How-
ever, we believe that we have cloned the bona ¢de
human DRG, because (1) the previously reported
human DRG is more similar to a Caenorhabditis
elegans GTP-binding protein than it is to the mouse
DRG [15], suggesting that it may be a GTP-binding
protein distinct from DRG; and (2) only one aa
di¡erence was identi¢ed between mouse DRG and
the human DRG that we had isolated (Fig. 3), sug-
gesting that clones L51 and V3 represent the genuine
human homologue of DRG.
First identi¢ed in the stem cell leukemia (SCL) cell
line DU528 [16], SCL is required for the develop-
ment of all hematopoietic cells [5^7]. SCL gene dis-
ruption and dysregulation occurs in V25% of T-cell
acute lymphoblastic leukemia patients [8,17].
Although initial experiments with transgenic mice
which overexpressed SCL failed to demonstrate
T-cell malignancies [11,18], collaborative expression
of SCL with LMO1, or LMO2 was recently demon-
strated to be tumorigenic in cross-bred transgenic
mice [11,19]. Heterodimerization between SCL and
LMO1 or LMO2, as demonstrated in vivo [19], sug-
gests that the cooperation between SCL and LMO1
in tumorigenesis may involve physical interactions as
well.
Speci¢c interaction between the SCL and DRG
proteins has now been demonstrated with human
(Fig. 1), as well as mouse proteins [4], but the sig-
ni¢cance of these interactions is not understood.
DRG has been localized to the cytoplasm [3], while
SCL is generally found in the nucleus, which would
seem to preclude a functional interaction between
these two proteins. However, SCL protein has re-
cently been detected in the cytoplasm during certain
phases of the cell cycle [20], supporting the possibility
that SCL and DRG may interact in the cytoplasm.
Further de¢nition of the functional relevance of this
interaction may be helpful in delineating the role of
SCL during hematopoietic development and leuke-
mic transformation.
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